Navigation Links
Cardiome And Astellas Announce Positive Results From ACT 2 Trial

st and telephone replays of the conference call will be available approximately two hours after the completion of the call through July 4, 2007. Please dial 416-695-5800 or 800-408-3053 and enter code 3225539 followed by the number sign to access the replay.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two late-stage clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), a Phase 1 program for GED-aPC, an engineered analog of recombinant human activated Protein C, and a pre-clinical program directed at improving cardiovascular function.

Vernakalant (iv) is the intravenous formulation of an investigational drug being evaluated for the acute conversion of atrial fibrillation (AF). Positive top-line results from two pivotal Phase 3 trials for vernakalant (iv), called ACT 1 and ACT 3, were released in December 2004 and September 2005. Cardiome's co-development partner Astellas Pharma US, Inc. submitted a New Drug Application for vernakalant (iv) in December 2006. Positive top-line results from an additional Phase 3 study evaluating patients with post-operative atrial arrhythmia, called ACT 2, were released in June 2007. An open-label safety study evaluating recent-onset AF patients, called ACT 4, is ongoing.

Vernakalant (oral) is being investigated as a chronic-use oral drug for the maintenance of normal heart rhythm following termination of AF. Cardiome announced positive results from a Phase 2a pilot study for vernakalant (oral) in September 2006. A Phase 2b study for vernakalant (oral) is ongoing.

In April 2007 Cardiome acquired exclusive worldwide rights for GED-aPC for all indications. Cardiome intends to initially develop GED-aPC in cardiogenic shock, a life-threatening form of acute circulatory failure due to cardiac dysfunction, which is a leading cause of death for patients hospitalized following a heart attack.

Cardiome is
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cardiome And Astellas Announce Positive Results From ACT Trial
(Date:5/22/2013)... , May 22, 2013 Z-Medica, a ... it has launched the first-ever line of products designed ... The line includes QuikClot ® EMS 4x4 Dressing, ... ® EMS Rolled Gauze™, all custom-designed to help ... they can be transported to a hospital or trauma ...
(Date:5/22/2013)... 22, 2013  MGT Capital Investments, Inc. (NYSE MKT: ... the Second Annual Marcum LLP MicroCap Conference on Thursday, ... at the Grand Hyatt Hotel.  ... will update investors and answer questions. (Logo: ... is scheduled to begin at 9:30 a.m. EDT.  MGT,s ...
(Date:5/22/2013)... , May 22, 2013 Hemoglobin A1C ... patients with Type 2 diabetes, while modest improvements ... health outcomes and can lead to substantial healthcare ... the International Society for Pharmacoeconomics and Outcomes Research ... two studies, sponsored by Valeritas, makers of the ...
Breaking Medicine Technology:Z-Medica Launches New Line of Hemostatic Agents for use in Emergency Medical Services 2MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 3MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 4Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 2Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 3Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 4Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 5Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 6
... 21, 2011  BARRX Medical Inc., a leader in developing ... to remove precancerous tissue from the gastrointestinal tract, announces ... be acquired by Covidien.  Covidien is a leading global ... advanced energy-based devices.  Covidien will acquire ...
... NORRITON, Pa., Nov. 21, 2011 Tengion, Inc. (NASDAQ: ... today announced that Brian Davis, Vice President Finance and ... upcoming Piper Jaffray 23rd Annual Health Care Conference on ... A live audio webcast of the presentation ...
Cached Medicine Technology:BARRX Medical, Inc. Announces Definitive Agreement to be Acquired by Covidien 2BARRX Medical, Inc. Announces Definitive Agreement to be Acquired by Covidien 3Tengion to Present at Piper Jaffray 23rd Annual Health Care Conference 2
(Date:5/22/2013)... Today, Zane Benefits, Inc. published a ... . Zane Benefits, which provides comprehensive and flexible alternatives ... in defined contribution plans and health ... beginning in 2014 as part of the Affordable Care ... businesses will become available through new state health insurance ...
(Date:5/22/2013)... hospitals may be reaping enormous income for patients ... infections contracted in their intensive care units. , ... the American Journal of Medical Quality , ... develops an avoidable central line-associated bloodstream infection (CLABSI) ... than a similar infection-free patient. Moreover, hospitals earn ...
(Date:5/22/2013)... Registered Dietitian and Founder of Tatalou Science ... sharing a recipe for making energy bars at home. , ... ,” takes a recipe modified from one recently featured ... day it gets more and more difficult to understand what ... size of the nutrition label continues to grow and consumers ...
(Date:5/22/2013)... WI (PRWEB) May 22, 2013 Unknown to ... their area at 30 mph. Minutes before it struck, ... of the nearing threat. This gave them time to reach ... & Data is proud to provide a product that ... occurs. A Wheelock SAFEPATH® SP40S Emergency Evacuation System ...
(Date:5/22/2013)... with heart failure are more likely to experience poorer ... mildly underactive, according to a new study. ... risk of death linked to the condition, which is ... first to show that African-Americans who have hypothyroidism face ... racial and ethnic groups," Dr. Connie Rhee, of Brigham ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 2Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 3Health News:Hospitals profit when patients develop bloodstream infections 2Health News:Hospitals profit when patients develop bloodstream infections 3Health News:Hospitals profit when patients develop bloodstream infections 4Health News:How To "Make Your Own Healthy Energy Bars" 2Health News:Telcom & Data Introduces Wheelock SAFEPATH® SP40S Emergency Evacuation System, An Effective Office Tool to Protect Employees from Severe Weather Threats 2Health News:Underactive Thyroid and Heart Failure a Bad Combination: Study 2
... it will open its first spa this autumn in Japan, ... ,The Armani Group is opening its giant ... part of its strategy to lure customers in Japan, already ... square-foot) complex opening on November 8 will include a spa ...
... minister on Wednesday lamented opposition from several states to a ... report said . ,"In our country, we do ... that is why we have a billion population," Health Minister ... Day. ,"In our close-knit society, we have to ...
... foods protect against the clustering of abnormal body chemistry known ... Journal of Epidemiology and Community Health. ,The syndrome has ... disease, and premature death. ,The findings are based ... and 59, all of whom were part of a long ...
... the more number of blemishes or moles you have, the slower you ... compared key ageing DNA with the number of moles in a study ... found that the more moles a person had, the more likely their ... for the spotted to rejoice, as this is in spite of the ...
... in London are long overdue but it is unclear how ... improve patient care in the capital , BMA leaders claim. ... Council, said: There is a case for changing how some ... of these proposals may not be in the best interests ...
... MP3s in a storm can literally blow your brains out as ... . ,Most people who are struck by lightning are not ... jumps from the object that was hit. ,In 2006, ... a side flash from a tree that had been struck. ...
Cached Medicine News:Health News:Dotted All Over? - Count Yourself Lucky 2Health News:Polyclinics Could Threaten NHS Services, Warns BMA 2
Suction Catheter Kits with Sterile Saline (Bottle)...
... These economy suction kits include ... pop-up solution basin and one ... exam gloves, without inner wallet. ... 5/6, 8 or 10 Fr ...
... Each kit includes a Tri-Flo® ... solution for flushing and lubrication, ... an inner wallet and a ... kits (5/6, 8 and 10 ...
Soft and flexible whistle tip catheter with 2 eye configuration. "Chimney" connector with standard tapered fit and thumb control. Available in sizes 6 18 French. Packaged straight....
Medicine Products: